Citation
Girard, P M., et al. "Long-term Outcome and Treatment Modifications in a Prospective Cohort of Human Immunodeficiency Virus Type 1-infected Patients On Triple-drug Antiretroviral Regimens. Triest Cohort Investigators." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 31, no. 4, 2000, pp. 987-94.
Girard PM, Guiguet M, Bollens D, et al. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators. Clin Infect Dis. 2000;31(4):987-94.
Girard, P. M., Guiguet, M., Bollens, D., Goderel, I., Meyohas, M. C., Lecomte, I., Raguin, G., Frottier, J., Rozenbaum, W., & Jaillon, P. (2000). Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 31(4), 987-94.
Girard PM, et al. Long-term Outcome and Treatment Modifications in a Prospective Cohort of Human Immunodeficiency Virus Type 1-infected Patients On Triple-drug Antiretroviral Regimens. Triest Cohort Investigators. Clin Infect Dis. 2000;31(4):987-94. PubMed PMID: 11049781.
TY - JOUR
T1 - Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators.
AU - Girard,P M,
AU - Guiguet,M,
AU - Bollens,D,
AU - Goderel,I,
AU - Meyohas,M C,
AU - Lecomte,I,
AU - Raguin,G,
AU - Frottier,J,
AU - Rozenbaum,W,
AU - Jaillon,P,
Y1 - 2000/10/25/
PY - 1999/11/29/received
PY - 2000/03/22/revised
PY - 2000/10/26/pubmed
PY - 2001/3/3/medline
PY - 2000/10/26/entrez
SP - 987
EP - 94
JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
JO - Clin Infect Dis
VL - 31
IS - 4
N2 - We designed a cohort in order to assess the long-term effects of triple-drug antiretroviral combinations in 608 patients infected with human immunodeficiency virus type 1 (HIV-1). We recruited patients who had been previously treated with nucleoside analogues as well as treatment-naive patients who were starting triple-drug antiretroviral combinations consisting of nucleoside analogues, either alone or in combination with a protease inhibitor. After a median follow-up time of 22 months, the incidence rates of acquired immune deficiency syndrome-defining events and death were, respectively, 6.9 (95% confidence interval [CI], 5.3-8.8) and 2.9 (95% CI, 1.9-4.2) per 100 person-years. Advanced clinical stage of disease (P=.004), a low CD4(+) cell count (P=.002), and a low quality-of-life score (P=.001) at baseline were independent predictors of clinical progression. The initial triple-drug combination was modified a total of 647 times in 321 patients. The only independent predictor of treatment modification was previous exposure to a nucleoside analogue in patients who did not receive a new nucleoside analogue at inclusion (P=.001). Plasma HIV RNA values below 500 copies/mL were obtained in 88% of the treatment-naive patients and in 57% of the previously treated patients (P<.001). Compared with previously treated patients who received > or = 1 new nucleoside analogue at enrollment, previously treated patients who did not receive a new nucleoside analogue at enrollment were twice as likely to have plasma HIV RNA values >500 copies/mL at the last visit (adjusted odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-2.8), and the antiretroviral-naive patients were significantly less likely to have plasma HIV RNA values >500 copies/mL at the last visit (adjusted OR, 0.2; 95% CI, 0.1-0.4).
SN - 1058-4838
UR - https://www.unboundmedicine.com/medline/citation/11049781/Long_term_outcome_and_treatment_modifications_in_a_prospective_cohort_of_human_immunodeficiency_virus_type_1_infected_patients_on_triple_drug_antiretroviral_regimens__Triest_Cohort_Investigators_
L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/318154
DB - PRIME
DP - Unbound Medicine
ER -